After Amylyx ALS trial failure, patients share disappointment and fear — but some hope
"If we fail, we get up again and again.” After Amylyx ALS trial failure, patients share disappointment and fear — but some hope.
The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient community hard.
An earlier study had shown that patients who took the drug for six months experienced significantly less decline than people on the placebo in physical function, such as the ability to speak, use utensils, or climb stairs. But while the Phase 2 results led to the drug’s approval by the Food and Drug Administration in 2022, they failed to replicate in a larger group.
What's Your Reaction?
